Introduction
============

The misuse of opioids, including prescription pain relievers, illegally produced opioids and heroin, is a growing public health concern. In 2015, an estimated 2.0 million people aged 12 years or older in the USA met the criteria for an opioid use disorder (OUD) involving prescription pain relievers in the past 12 months, and 0.6 million individuals had an OUD involving heroin in the past 12 months.[@b1-sar-9-059] (The term "opioid use disorder" was introduced in the *Diagnostic and Statistical Manual of Mental Disorders*, fifth edition.[@b2-sar-9-059] Previously, the terms "opioid dependence" and "opioid abuse" were used to diagnose corresponding conditions). Furthermore, the USA is amid a national opioid overdose epidemic with the rate of opioid-related overdose deaths increasing by more than 200% in the past 15 years.[@b3-sar-9-059] In addition to death from overdose, OUD has been associated with blood-borne infections such as hepatitis and HIV, criminal involvement, productivity losses and increased health care utilization and costs.[@b4-sar-9-059]--[@b10-sar-9-059] The resulting economic burden is significant with recent estimates of the societal costs of OUD and opioid overdose exceeding \$78 billion.[@b6-sar-9-059]

Treatment for OUD is important because of the negative consequences of illicit opioid use; however, treating OUD patients is often challenging as OUD is a chronic disease characterized by episodes of relapse and remission.[@b11-sar-9-059] Current treatment options include psychosocial therapy and medication-assisted treatment (MAT) with methadone, buprenorphine (alone or in combination with naloxone) or naltrexone.[@b11-sar-9-059] Buprenorphine MAT, a commonly used therapy and the focus of this study, is an effective treatment option that is available in outpatient office-based settings through waivered clinicians.[@b12-sar-9-059],[@b13-sar-9-059] From 2000 to 2016, only physicians were eligible to apply for and receive waivers. In 2016, US federal regulations extended waivering to nurse practitioners (NPs) and physician assistants (PAs). In some states, buprenorphine prescribing may be limited to waivered physicians, or NPs and PAs working under a waivered physician, due to state-level scope-of-practice laws.

A previous study found that buprenorphine MAT was associated with a reduced incidence of relapse among patients with OUD.[@b14-sar-9-059] In addition, it has been shown that opioid-dependent patients adherent to buprenorphine MAT in the year following treatment initiation had reduced utilization of expensive health care services[@b15-sar-9-059]--[@b17-sar-9-059] and total health care costs.[@b15-sar-9-059],[@b16-sar-9-059] However, these reductions were among patients in a single Commercial health plan[@b15-sar-9-059],[@b16-sar-9-059] or in one state Medicaid plan,[@b17-sar-9-059] and to the authors' knowledge no study has explored the effect of adherence on outcomes in large real-world samples of patients from different health plans throughout the USA.

The primary objective of this study was to understand the relationship between buprenorphine MAT adherence and odds of relapse, health care resource utilization and costs among both commercially insured and publicly insured (ie, Medicaid) patients with OUD who were newly initiating buprenorphine MAT. The secondary objective was to identify factors associated with buprenorphine MAT adherence. This study expands on the insights gained from prior studies by examining the impact of adherence among a large, national sample of individuals with OUD.

Patients and methods
====================

Study design and data source
----------------------------

This retrospective, observational cohort study used administrative claims data from the MarketScan^®^ Commercial Claims and Encounters (Commercial)[@b18-sar-9-059] and Medicaid Multi-State (Medicaid)[@b19-sar-9-059] Research Databases. The Commercial Database includes fully adjudicated medical and pharmacy claims for more than 100 million employees and their dependents from across the USA including more than 38 million lives in 2013 alone. Major data contributors include employers and health plans that cover employees and their dependents through different insurance plan structures including fee-for-service, fully capitated and partially capitated health plans. The Medicaid Database includes similar information for Medicaid beneficiaries in several geographically dispersed states. Both databases provide detailed cost, utilization and outcome data for health care services performed in both inpatient and outpatient settings, including retail and mail order outpatient pharmacies. All study data were de-identified and fully compliant with the Health Insurance Portability and Accountability Act (HIPAA) of 1996. The study entailed analyses of existing databases in which subjects could not be identified. Therefore, the study was not considered human subject research and did not require institutional review board (IRB) approval.

Study population
----------------

Patients of any age with at least one outpatient pharmacy claim for buprenorphine from January 1, 2008, to March 31, 2014, in the Commercial Database or June 30, 2014, in the Medicaid Database were selected for analysis. The date of the earliest buprenorphine claim was set as the index date. Patients were required to have at least one inpatient or outpatient service claim including a diagnosis of opioid dependence or abuse (International Classification of Diseases, Ninth Revision, Clinical Modification \[ICD-9-CM\] 304.0×, 304.7× or 305.5×) prior to or on the index date. Patients with index dates in 2008 may have been identified in the middle of a treatment episode; thus, patients with outpatient pharmacy claims for buprenorphine in the 3 months prior to the index date were excluded to of the index date. Continuous enrollment with medical and pharmacy benefits for 6 months prior to and 12 months following the index date was required for study inclusion. Patients from database contributors that may have mental health and substance abuse carve-outs that do not share data with the plan were excluded because claims in the database for these patients may not represent all covered health care utilization. Patients treated with an average daily dose of buprenorphine of less than 4 mg/day and who remained on treatment less than 30 days were excluded, as these patients were likely to be detoxification patients rather than patients using buprenorphine MAT as maintenance therapy. Medicaid patients were excluded if they had dual Medicaid/Medicare eligibility because services covered in full by Medicare may not be included in the MarketScan Medicaid Multi-State Database. Patients were followed up over 12 months, commencing on the index date (ie, at buprenorphine initiation).

Adherence
---------

Buprenorphine MAT adherence was measured using the proportion of days covered (PDC) by buprenorphine in the 12 months following treatment initiation. The total days of possession of buprenorphine were calculated from the days of supply information on outpatient pharmacy claims, regardless of gaps in therapy. For patients who refilled early, overlapping days were appended to the total days of supply. PDC was then calculated as: $$\text{PDC} = \frac{\text{Sum~of~days~supply~in~the~study~period}}{\text{Days~in~the~folllow-up~period}(365\ \text{days})}$$Patients were grouped by PDC into the following categories: PDC\<0.20, 0.20≤PDC\<0.40, 0.40≤PDC\<0.60, 0.60≤PDC\<0.80 and PDC≥0.80. Patients with PDC≥0.80 were classified as adherent, consistent with previous studies in this disease area[@b15-sar-9-059],[@b16-sar-9-059] and other chronic conditions.[@b20-sar-9-059]

Outcome measures
----------------

### Relapse prevalence

Relapse prevalence was measured during the follow-up period of the study. Relapses are not directly captured in claims data, so a proxy measure based on services that may be indicators of relapse was employed. The proxy measure, which was a modification of a measure used in previous claims-based studies,[@b21-sar-9-059],[@b22-sar-9-059] defined relapse as the presence of claims for any of the following binary (yes/no) relapse indicators: Diagnosis code of opioid dependence, continuous or episodic (ICD-9-CM 304.01, 304.02, 304.71, 304.72), following an opioid dependence in remission code (ICD-9-CM 304.03, 304.73)Inpatient admission with a primary diagnosis related to opioid use (opioid dependence, opioid abuse or opioid overdose \[ICD-9-CM 965.09\])Detoxification with any diagnosis related to opioid useEmergency department (ED) visit with any diagnosis related to opioid useBased on the clinical experience of one of the authors (BAW) in treating patients with OUD and given the limitations of the claims data used in this study, these indicators were chosen as proxies for relapse, which could capture both apparent relapses (eg, inpatient admission and ED visit) and relapses identified by treating clinicians at an earlier stage (eg, diagnosis code change and detoxification). Each indicator was measured separately for descriptive review. Patients with one or more relapse indicator at any time during the 12 months following buprenorphine MAT initiation were categorized as having relapsed for the purposes of modeling.

### Health care utilization and costs

All-cause health care utilization and costs were evaluated during the 12-month post-index period. Specific utilization measures included inpatient admissions, ED visits, physician office visits and outpatient pharmacy services. Corresponding costs were measured from the paid amounts on relevant claims, including both the patient responsibility (eg, deductible, copay or coinsurance) and the health plan payment (including coordination of benefit amount). Cost categories were created by summing costs across all relevant claims. Inpatient costs were defined as all costs related to an admission. Outpatient costs included costs from ED visits, physician office visits and other non-pharmacy outpatient services. Medical costs comprised inpatient plus outpatient costs, and total costs comprised medical costs plus outpatient pharmacy costs. If the sum of a patient's costs across all claims in a category was less than zero, which occasionally happens in claims data if claims are erroneously reconciled, the patient's costs for that category were set to zero. No trimming of high-end cost outliers was conducted. Similar health care utilization and cost measures were calculated from claims in the 6-month pre-index period to compare against the post-index measures. All cost estimates were inflation adjusted to 2014 US dollars, using the medical component of the Consumer Price Index.

Other variables
---------------

Patient demographics including age in years, sex, race (Medicaid Database only), geographic region of residence (Commercial Database only), urban/rural residence, insurance plan type and relationship to the policyholder (Commercial Database only) were measured on the index date. Sex is a binary variable (male, female) in the databases used for this analysis. Race, in the Medicaid Database was categorized as follows: White (not of Hispanic ethnicity); Black (not of Hispanic ethnicity); Hispanic (regardless of race) and others (American Indian/Alaskan Native, Asian or native Hawaiian/other Pacific Islander). Geographic region in the Commercial Database is based on US census regions, which include Northeast, Northcentral (Midwest), South and West. The urban/rural residence designation in the databases is based on whether place of residence is located within a US metropolitan statistical area (urban) or not (rural). Insurance plan type (eg, preferred provider organization \[PPO\] and health maintenance organization \[HMO\]) and the relationship to the policyholder (Commercial Database only, ie, employee, spouse or child/others) were categorized as recorded on the index buprenorphine claim.

The Deyo-Charlson Comorbidity Index (DCI)[@b23-sar-9-059] was calculated from claims during the 6-month pre-index period. The DCI is an aggregate measure of comorbidity, expressed as a numeric score, based on the presence of diagnoses for selected chronic conditions (ie, cerebrovascular disease, congestive heart failure, chronic pulmonary disease, dementia, diabetes, hemiplegia or paraplegia, HIV/AIDS, liver disease, malignancy \[any\], metastatic solid tumor, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease and rheumatologic disease), which are assigned weights ranging from 1 to 6 points. Weights for all conditions recorded in the patient's claims are summed to produce the DCI score. The range of possible scores is 0--33 with higher scores reflective of greater comorbid burden.

Specific pre-index comorbid conditions were measured based on the presence of one or more non-diagnostic claim in the 6-month pre-index period carrying a diagnosis code indicative of the condition. Only non-diagnostic claims -- that is, claims other than for laboratory and radiology services -- were used to create the comorbid condition variables, because diagnostic claims may list rule-out conditions rather than actual comorbidities. Comorbidity variables included non-opioid drug use disorder, alcohol use disorder, depressive disorder, bipolar disorder, generalized anxiety disorder, schizophrenia, chronic pain condition (eg, migraine, headache syndromes, spondylosis, disc disorders, cervicalgia, torticollis, neuropathies, osteoarthritis, rheumatoid arthritis, endometriosis, chronic pancreatitis, chronic postoperative or trauma pain), HIV/AIDS, hepatitis B and hepatitis C. The comorbid non-opioid drug use disorder variable measured disorders involving substances other than opioids, alcohol and tobacco, including sedatives, hypnotics, anxiolytics, cocaine, cannabis, amphetamines, non-amphetamine psychostimulants, hallucinogens, antidepressants and other unspecified substances. Opioids were not included in this variable because all patients in the study had evidence of OUD on or prior to the index date, and the intent was to measure comorbid drug use disorders related to non-opioid substances. Alcohol was not included when measuring non-opioid drug use disorder because pre-index comorbid alcohol use disorder was measured with a separate variable.

Concomitant medication use was measured based on one or more outpatient pharmacy claim in the 6-month pre-index period for the following medication classes: opioid analgesics excluding buprenorphine and methadone (eg, codeine, fentanyl, hydrocodone, hydromorphone, meperidine, morphine, oxycodone, oxymorphone, pentazocine, propoxyphene and tapentadol), benzodiazepines, non-benzodiazepine sedative/hypnotics, antidepressants and antipsychotics. An outpatient services claim for an injectable antipsychotic also was considered evidence of concomitant antipsychotic use. MAT other than buprenorphine MAT (ie, methadone MAT, oral naltrexone MAT and extended-release injectable naltrexone MAT) was measured based on one or more relevant claim in the 6-month pre-index period. Psychosocial treatment was measured in the 12-month post-index period.

Buprenorphine dosing variables were created to include as covariates in modeling because previous studies suggested that buprenorphine dose may impact subsequent treatment retention and adherence.[@b24-sar-9-059],[@b25-sar-9-059] The average daily dose of buprenorphine was measured over the first 6 months post-index to assess the association between dosing in the initial months of treatment and medication adherence over the 12-month follow-up period. Average daily dose was calculated from information on pharmacy claims by determining the milligrams of product dispensed at each fill (ie, tablet strength × number of tablets) and performing the following calculation: $$\text{Average~daily~dose} = \frac{\text{Total~milligrams~dispensed~in~the~time~frame}}{\text{Sum~of~days~supply~in~the~time~frame}}$$Access restrictions (eg, prior authorization) imposed by state Medicaid agencies may affect buprenorphine adherence. Thus, for the Medicaid analysis, a variable was created to indicate the presence of any of the following restrictions on access to buprenorphine: daily dose limit of 16 mg or less, lifetime treatment length limit of 1 year or less or prior authorization frequency of ≤6 months. This variable could not be reported descriptively due to confidentiality agreements with database contributors, but was included as a covariate when modeling buprenorphine adherence.

Statistical analyses
--------------------

The Commercial and Medicaid samples were analyzed separately in parallel analyses. The patient group with PDC≥0.80 (ie, patients defined as adherent) was the reference category for all statistical comparisons. Chi-squared tests and Student's *t*-tests were used to evaluate the statistical significance of differences in patient characteristics between PDC categories for categorical variables and continuous variables, respectively. For categorical variables, when more than 20% of cells in a comparison had expected observations of 5 or fewer, Fisher's exact tests were used. An a priori *p*-value of \<0.05 was set as the threshold for statistical significance.

Adjusted analyses were conducted to examine the impact of PDC on relapse and total health care costs in the year following buprenorphine MAT initiation and to assess the factors of adherence to buprenorphine MAT. Relapse in the 12 months following treatment initiation, a binary (yes/no) variable, was modeled via standard logistic regression. In addition to the PDC category, covariates in the relapse models included the following: age, sex, race (Medicaid only), relationship to policyholder (Commercial only), insurance plan type, pre-index alcohol use disorder diagnosis, pre-index non-opioid drug use disorder diagnosis, pre-index severe mental illness diagnosis (schizophrenia and/or bipolar disorder), pre-index other mental illness diagnosis (depressive disorder and/or generalized anxiety disorder) and pre-index chronic pain condition diagnosis. Examination of Schoenfeld residuals[@b26-sar-9-059] and variation inflation factors[@b27-sar-9-059] for each covariate confirmed the appropriateness of the model structure and absence of high correlation between covariates, respectively.

Generalized linear models (GLMs) with a log link and underlying gamma distribution were used to model the cost data. The same set of covariates used in the relapse models was included in the cost models. Model diagnostics suggested that the models may overestimate costs for some covariates among very expensive patients. Costs were, therefore, adjusted based on the GLM coefficients for the key explanatory variable of PDC category as well as for other variables that the analysis suggested may be cost drivers (Commercial: relationship to policyholder, pre-index chronic pain condition diagnosis; Medicaid: insurance plan type, pre-index severe mental illness diagnosis) in case model trends were dissimilar across subgroups.

Factors associated with adherence were identified in a logistic regression model that estimated the impact of patient characteristics on being in the adherent cohort (ie, having PDC≥0.80 vs. PDC\<0.80). Covariates were similar to those used in the relapse and cost models, except that PDC categories were not included as covariates since PDC was used to define the dependent variable of adherence. In addition, the following covariates were added to assess their association with adherence: geographic region (Commercial only); urban/rural residence; Medicaid access restrictions on buprenorphine (Medicaid only); pre-index MAT other than buprenorphine MAT; buprenorphine average dose in the first 6 months post-index and post-index psychosocial treatment. The review of variation inflation factors[@b27-sar-9-059] confirmed that there was no high multicollinearity between model covariates.

All data management, descriptive analyses, bivariate analyses and adjusted analyses were conducted using SAS 9.4 (SAS Institute Inc, Cary, NC, USA).

Results
=======

Patient selection and PDC groups
--------------------------------

A total of 16,085 commercially insured patients and 5,688 Medicaid patients were qualified for the analysis ([Figure 1](#f1-sar-9-059){ref-type="fig"}). In the Commercial sample, 37.1% of patients were classified as adherent based on PDC≥0.80. Among the non-adherent patients, 28.4% had PDC\<0.20, 13.2% had 0.20≤PDC\<0.40, 10.7% had 0.40≤PDC\<0.60 and 10.7% had 0.60≤PDC\<0.80. In the Medicaid sample, 41.3% of patients were adherent. Among the non-adherent patients, 26.7% had PDC\<0.20, 12.6% had 0.20≤PDC\<0.40, 10.5% had 0.40≤PDC\<0.60 and 8.9% had 0.60≤PDC\<0.80.

Patient characteristics
-----------------------

Baseline patient demographics and clinical characteristics are presented in [Table 1](#t1-sar-9-059){ref-type="table"} (Commercial) and [Table 2](#t2-sar-9-059){ref-type="table"} (Medicaid). The majority of patients in the Commercial sample were male (62.7%), while the majority of Medicaid patients (72.6%) were female. The high proportion of female patients in the Medicaid sample is consistent with the high female-to-male ratio among Medicaid beneficiaries in the underlying database, which is likely related to Medicaid eligibility requirements. The overall study sample in both the Commercial and Medicaid samples had an average age of 32 years. Commercial patients with PDC≥0.80 were slightly older and more likely to be the insured employee (as opposed to a dependent) than those with lower adherence. Among Medicaid patients, the proportion of Black patients was higher among patients with PDC\<0.20 (12.1%), 0.20≤PDC\<0.40 (6.3%) and 0.40≤PDC\<0.60 (6.4%) as compared to patients with PDC≥0.80 (4.3%).

In both the Commercial and Medicaid samples, significantly higher (*p*\<0.001) rates of baseline alcohol use disorder, non-opioid drug use disorder, depressive disorder and bipolar disorder were observed in those with PDC\<0.20 than among adherent patients (PDC≥0.80). A higher rate of chronic pain conditions was observed among Medicaid patients with the lowest level of adherence (PDC\<0.20) compared to adherent patients (*p*\<0.001). Medicaid patients with PDC\<0.20 had higher rates of concomitant medication use including opioid analgesics, benzodiazepines, non-benzodiazepine sedative/hypnotics, antidepressants and antipsychotics than adherent patients (opioid analgesics, *p*=0.007; all other medication classes, *p*\<0.001).

Relapse prevalence
------------------

In the Commercial sample, 21.2% of patients had at least one indicator of relapse during the 12-month post-index period with the lowest prevalence of relapse observed in patients with PDC≥0.80 (11.4%). The proportion of patients with at least one indicator of relapse was significantly higher in each of the lower adherence groups compared to the adherent group ([Table 3](#t3-sar-9-059){ref-type="table"}). The same trend was observed when each relapse indicator was considered individually, except for the indicator measuring a diagnosis code of opioid dependence, continuous or episodic, following an opioid dependence in remission code, which was significantly different between the lowest adherence group (PDC\<0.20) and the adherent group (PDC≥80%), but similar across other PDC groups.

In the Medicaid sample, 15.0% of patients had at least one indicator of relapse during the 12-month post-index period with the lowest relapse prevalence observed in adherent patients (10.0%). Similar to the trend observed in the Commercial sample, the proportion of Medicaid patients with an indicator of relapse was significantly higher in each of the lower adherence groups compared to the adherent group ([Table 3](#t3-sar-9-059){ref-type="table"}). The same trend was observed when each relapse indicator was considered individually, except for the indicator measuring a diagnosis code of opioid dependence, continuous or episodic, following an opioid dependence in remission code, which was significantly different between the two lowest adherence groups (PDC\<0.20, 0.20≤PDC\<0.40) and the adherent group (PDC≥80%), but similar across other PDC groups. In contrast to relapse prevalence in the Commercial sample, an ED visit with any diagnosis related to opioid use was the most common individual relapse indicator among Medicaid patients.

After adjustment to control for differences between cohorts, Commercial patients in all other PDC groups had significantly higher odds of experiencing at least one indicator of relapse in the 12 months post buprenorphine MAT initiation compared to the reference group of adherent patients with PDC≥80% (PDC\<0.20: adjusted odds ratio \[AOR\]=2.02, 95% CI=1.77--2.32; 0.20≤PDC\<0.40: AOR=2.33, 95% CI=1.99--2.74; 0.40≤PDC\<0.60: AOR=2.27, 95% CI=1.92--2.70; 0.60≤PDC\<0.80: AOR=1.65, 95% CI=1.37--1.98; all *p*\<0.001). Similar results were observed among Medicaid patients in the 12-month post-index period (PDC\<0.20: AOR=1.76, 95% CI=1.40--2.20; 0.20≤PDC\<0.40: AOR=1.90, 95% CI=1.45--2.50; 0.40≤PDC\<0.60: AOR=1.65, 95% CI=1.22--2.23; 0.60≤PDC\<0.80: AOR=1.48, 95% CI=1.06--2.06; all *p*\<0.01; [Table 4](#t4-sar-9-059){ref-type="table"}).

Health care utilization and costs
---------------------------------

[Table 3](#t3-sar-9-059){ref-type="table"} presents the unadjusted health care resource utilization and costs by the PDC group in the 12 months following buprenorphine MAT initiation. In both the Commercial and Medicaid samples, the proportion of patients with an inpatient admission in the 12 months following the index date was significantly higher in the non-adherent groups compared to the adherent cohort. The proportion of patients hospitalized in the lowest non-adherent group (PDC\<0.20) was about twice that of patients with PDC≥80% (Commercial: 44.3% vs. 17.9%, *p*\<0.001; Medicaid: 39.0% vs. 19.9%, *p*\<0.001). A similar pattern was observed for ED utilization (Commercial: 55.0% vs. 34.5%, *p*\<0.001; Medicaid: 79.6% vs. 65.0%, *p*\<0.001). Adherent patients had a significantly higher number of physician office visits post buprenorphine MAT initiation than non-adherent patients. In both the Com mercial and Medicaid samples, patients with PDC≥80% incurred about 13 physician office visits, on average, over the 12-month post-index period, compared to about eight visits for patients with PDC\<0.20 (*p*\<0.01). The difference may be explained, in part, by office visits required for buprenorphine MAT initiation and monitoring. As expected given the association between medication adherence and prescription fills, adherent patients also had a higher number of pharmacy claims than non-adherent patients.

The average unadjusted total health care costs in the 12-month post-index period were \$23,006 and \$19,888 for the patients in the Commercial and Medicaid samples, respectively. In the Commercial sample, the mean unadjusted total health care costs decreased as adherence levels increased from \$28,525 in patients with PDC\<0.20 to \$17,844 in patients with PDC≥0.80. The average health care costs in the Medicaid sample decreased slightly from \$21,292 in patients with PDC\<0.20 to \$18,621 in patients with PDC≥0.80. Mean unadjusted outpatient pharmacy costs increased with adherence in both Commercial and Medicaid patients while medical costs decreased with adherence levels. The large standard deviations as given in [Table 3](#t3-sar-9-059){ref-type="table"} are typical of health care cost data, which are often highly skewed. This study's inclusion criteria required all patients to have buprenorphine MAT utilization at index so there was not a cluster of patients with zero total costs; however, there were some patients with very high costs that resulted in large SDs around the mean costs.

[Table 5](#t5-sar-9-059){ref-type="table"} presents the adjusted mean total health care costs in the 12 months post buprenorphine MAT initiation for the Commercial and Medicaid samples. After adjusting for differences between PDC groups using GLMs, mean total costs in the Commercial sample decreased as adherence increased, with adherent patients (PDC≥0.80) having significantly lower adjusted mean total costs (\$17,519) as compared to patients in all non-adherent groups (PDC\<0.80; range from \$20,294 to \$24,431). Other factors that were found to significantly affect the health care costs in the Commercial sample included relationship to policyholder and having a comorbid chronic pain condition. Adjusted mean total costs were significantly lower for insured employees (\$18,570) than for covered dependents (spouses, \$20,325; children/others, \$27,073). Contrarily, the adjusted mean total costs of Commercial patients with a pre-index chronic pain condition were significantly higher (\$24,995) than similar patients with no pre-index claims indicative of a chronic pain condition (\$18,840).

In the Medicaid sample, adjusted mean total costs were not significantly different between adherent (PDC≥0.80) and non-adherent groups (PDC\<0.80). Factors found to significantly affect the health care costs in the Medicaid sample included managed care plan type and severe mental illness comorbidity status. Adjusted mean total costs for patients in Medicaid managed care plans were higher (\$22,777) than for Medicaid patients in non-managed care plans (\$19,371). Patients with a pre-index severe mental illness had significantly higher adjusted mean total costs in the 12-month post-index period (\$24,146) than patients with no claims evidence of such a condition (\$18,273).

Factors associated with adherence
---------------------------------

Variables in the logistic regression models that were significantly associated with increased odds of adherence (PDC≥0.80) in Commercial patients ([Figure 2](#f2-sar-9-059){ref-type="fig"}) included receipt of psychosocial therapy post-index (AOR=1.26, 95% CI=1.173--1.348), rural residence vs. urban (AOR=1.21, 95% CI=1.098--1.335), and Northeast geographic region vs. South (AOR=1.20, 95% CI=1.095--1.312). Factors significantly associated with decreased odds of adherence were being a child or other dependent of the policyholder vs. being the employee (AOR=0.37, 95% CI=0.335--0.414), being a spouse of the policyholder vs. being the employee (AOR=0.81, 95% CI=0.746--0.885), average daily dose of buprenorphine MAT \<12 mg vs. 12--24 mg (AOR=0.61, 95% CI=0.570--0.656), pre-index severe mental illness diagnosis (AOR=0.73, 95% CI=0.631--0.834), pre-index non-opioid drug use disorder diagnosis (AOR=0.79, 95% CI=0.726--0.852), pre-index alcohol use disorder diagnosis (AOR=0.83, 95% CI=0.737--0.926), pre-index chronic pain diagnosis (AOR=0.90, 95% CI 0.834--0.966) and West geographic region vs. South (AOR=0.85, 95% CI=0.773--0.944).

In the Medicaid sample, variables significantly associated with increased odds of adherence based on logistic regression models ([Figure 3](#f3-sar-9-059){ref-type="fig"}) included female (AOR=1.23, 95% CI=1.085--1.400) and average daily dose of buprenorphine MAT \>24 mg vs. 12--24 mg (AOR=1.49, 95% CI=1.194--1.869). Factors significantly associated with decreased odds of PDC≥0.80 were average daily dose of buprenorphine MAT \<12 mg vs. 12--24 mg (AOR=0.42, 95% CI=0.368--0.488), managed care plan type vs. non-managed care plan type (AOR=0.57, 95% CI=0.495--0.653), pre-index non-opioid drug use disorder diagnosis (AOR=0.75, 95% CI=0.662--0.840), pre-index severe mental illness diagnosis (AOR=0.78, 95% CI=0.674--0.904), pre-index chronic pain condition diagnosis (AOR=0.83, 95% CI=0.742--0.935) and pre-index alcohol use disorder diagnosis (AOR=0.80, 95% CI 0.658--0.978).

Discussion
==========

This study assessed adherence in the 12 months following buprenorphine MAT initiation among OUD patients and found that 37% of Commercial patients and 41% of Medicaid patients were classified as adherent, based on PDC of 0.80 or above. The Commercial adherence rate is similar to the findings of two previous retrospective claims database studies utilizing a single US commercial health plan population. One study[@b15-sar-9-059] found that 32% of patients were adherent to buprenorphine MAT in the year following treatment initiation, while the other[@b16-sar-9-059] determined that 36%--43% were adherent, depending on the adherence definition used. The Medicaid adherence rate in this study based on a multistate sample appeared higher than results from a previous analysis of data from one state Medicaid program.[@b17-sar-9-059] Different adherence measures between the two studies make direct comparison difficult, but the previous analysis found that only 21% of patients persistently refilled buprenorphine over 12 months following treatment initiation.

The association between adherence and reduced odds of relapse was consistent with expectations and confirmed previous studies in other patient samples.[@b14-sar-9-059],[@b16-sar-9-059],[@b22-sar-9-059] Patients with lower levels of buprenorphine MAT adherence had significantly increased odds of relapse compared to adherent patients, lending further evidence that buprenorphine MAT adherence is associated with improved treatment outcomes.

Among Commercial patients, after controlling for demographic characteristics and comorbidities, higher levels of adherence were associated with lower total costs, and the effect was larger as the adherence level increased. Adherent patients' (PDC≥0.80) adjusted total health care costs were nearly 30% less than non-adherent patients', despite the higher pharmacy costs of buprenorphine MAT for adherent patients. This analysis did not separately measure buprenorphine pharmacy costs, but the \$350 to \$420 estimated monthly cost of buprenorphine[@b28-sar-9-059] might account for part of the outpatient pharmacy cost difference between adherent and non-adherent patients. For Medicaid patients, descriptive analysis found that adherence was associated with higher outpatient pharmacy costs and lower medical costs, resulting in lower total costs. The models controlling for demographic characteristics and comorbidities found no association between buprenorphine MAT adherence and total costs, which indicates that the reduction in total costs among adherent patients in the descriptive analyses of the Medicaid population is likely explained by other clinical or demographic factors that are prevalent in the adherent population.

The total cost trends observed in the Commercial sample after adjustment are consistent with two recent analyses of buprenorphine-treated patients.[@b15-sar-9-059],[@b16-sar-9-059] Tkacz et al[@b15-sar-9-059] analyzed health care charges (as opposed to paid amounts) and found adherent patients to have significantly lower adjusted total charges over the 12-month post-index period, as compared to non-adherent patients (\$28,458 vs. \$49,051, *p*=0.001). Ruetsch et al[@b16-sar-9-059] assessed costs (paid amounts) and similarly found adjusted total costs over the 12-month post-index period to be lower among adherent than non-adherent patients (\$7,581 vs. \$10,638, *p*\<0.01). Both these studies analyzed a single health plan population, and findings from analyses of a single plan may reflect a benefit design or member or clinician population that is unique to that plan. However, the similar trends in the current study, which included patients from several commercial fee-for-service and managed care plans across the USA, suggest that buprenorphine MAT adherence may be a key factor for reducing costs across commercial plans.

The current study's Medicaid cost trends appear to conflict with the intuitive association between buprenorphine adherence and better health outcomes leading to reduced health care costs, but several factors may have impacted this association. First, when comparing the distribution of total costs among Medicaid patients to that of Commercial patients, the cost variation within group was notably higher among the Medicaid patients. This may mean Medicaid patients are a more heterogeneous group and include patients with multiple preexisting comorbidities who require personalized approaches to OUD management. Furthermore, Medicaid patients often struggle with limited and restricted provider networks that result in limited access to addiction specialists, long waiting times for appointments and transportation issues. In addition, Medicaid patients may have also experienced access challenges in other treatment areas. Health care systems for substance use disorder treatment are often fragmented and poorly funded.[@b29-sar-9-059] As found in our study, comorbidities such as alcohol use disorder, schizophrenia, depressive disorder and bipolar disorder were more prevalent among patients who were not adherent to buprenorphine MAT. These comorbidities may complicate navigating the health care system efficiently to receive treatments to address the consequences of non-adherence to the medication, especially when being forced to rely on Medicaid providers and funding. Certain patients may be adherent due to close monitoring by physicians because of the seriousness of the patient's situation (eg, patients with multiple comorbidities or legal system interaction), thus resulting in improved medication adherence and also health care costs for close monitoring and treatment. Unmeasurable characteristics or interactions between risk factors and adherence that could not be controlled for in modeling also may have impacted the cost model results.

There is no optimal duration of maintenance therapy with buprenorphine. Treatment guidelines[@b11-sar-9-059],[@b30-sar-9-059] suggest that short- or long-term treatment may be appropriate depending on several factors, most of which cannot be measured in claims data (eg, patient preference for continued treatment, psychosocial support, stable home situation and absence of legal problems). Thus, while patients with PDC of 0.80 or above (about 9 or 10 months of therapy) were the reference group in the current study, there could be treatment successes across all PDC groups. Other studies[@b16-sar-9-059] found patients with PDC between 0.60 and 0.79 to have costs similar to those of patients with PDC≥0.80, suggesting that some patients may have adequate cost outcomes at slightly lower adherence levels.

A number of patient characteristics were found to be predictive of non-adherence, suggesting several opportunities for patients, clinicians and payers to improve buprenorphine MAT adherence. Comorbid conditions such as alcohol use disorder, non-opioid drug use disorder, severe mental illness (schizophrenia and/or bipolar disorder), chronic pain conditions and lower average daily dose of buprenorphine MAT (\<12 mg) were significantly associated with buprenorphine MAT non-adherence. In commercially insured patients, the use of psychosocial therapy in addition to buprenorphine MAT was associated with increased odds of adherence while being a spouse, child or other dependent of the primary policyholder was associated with decreased odds of adherence. The adequate identification and management of mental health conditions and other substance use disorders among opioid-dependent patients receiving buprenorphine MAT should be a key treatment focus. Careful selection and monitoring of buprenorphine MAT doses may also improve patient adherence. In addition, children or spouses of commercial insurance policyholders should be given extra support to remain on therapy.

As with any retrospective claims analysis, this study had several limitations. Administrative claims data are subject to data coding limitations and data entry error. Substance use disorders tend to be under-recorded in claims data, due to various factors including access to care (including screening and treatment) issues,[@b29-sar-9-059] stigma,[@b31-sar-9-059] privacy concerns[@b32-sar-9-059] and billing practices.[@b33-sar-9-059] Sensitivity of substance use disorder coding in claims data is generally high but specificity may be low,[@b34-sar-9-059] such that there is potential for misclassification of outcomes that depend on the presence of OUD diagnoses on claims. This study was limited to individuals with commercial coverage through an employer and Medicaid beneficiaries from select states and results may not be generalizable to patients with other types of coverage or with no health insurance coverage. The PDC cohorts were created based on information present on claims and may be subject to measurement error. PDC was based on days' supply of medication dispensed. It was not possible to ascertain from claims whether patients actually took all days of therapy that was dispensed. Similarly, potential drug diversion could not be ascertained from claims data. It is possible that patients who appeared to be adherent to buprenorphine MAT actually were not due to diversion. Relapse was identified using service-based proxies that, while informed by expert opinion and prior study, have not been validated and, thus, may have misclassified some patients. It is likely the relapse proxy underestimates actual relapse prevalence since relapse does not necessarily result in health care utilization within a defined time frame. That said, false positives also are possible, as reasons other than relapse may result in some of the relapse indicator services. For example, the presence of a diagnosis code of opioid dependence, continuous or episodic, following an opioid dependence in remission code could represent patients undergoing evaluation when switching buprenorphine MAT clinicians. Finally, the adjusted analysis was limited to controlling for factors that could be measured from claims data. Differences between cohorts could have remained after adjustment and may have impacted findings. For example, it was not possible to measure and control for disease severity, psychosocial supports, legal system involvement, ease of access to heroin/opioids or other related factors that may have impacted outcomes.

Conclusion
==========

Adherence to buprenorphine MAT in the 12 months following treatment initiation was low, with only 37% of Commercial and 41% of Medicaid patients having PDC≥0.80. In contrast, treatment adherence was associated with reduced odds of relapse and medical costs in both Commercial and Medicaid patients. Specifically, for Commercial patients who were treatment adherent, the reduction in their medical costs exceeded the increased pharmacy costs to the level where the total costs for adherent patients were predicted to be 30% lower than those among the PDC\<0.20 group. In comparison, the reduction in medical costs among Medicaid patients was just enough to offset the increased pharmacy costs, which may be because Medicaid patients are a more heterogeneous group who require personalized approaches to OUD management. Additional studies, especially prospective studies that follow patients over multiple years, are needed to better understand the relationship between treatment, adherence and long-term health outcomes in patients with OUD to optimize treatment for these patients.
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![Predictors of adherence (PDC≥0.80) among adult patients with OUD who were newly initiating buprenorphine MAT: Commercial sample.\
**Note:** Based on logistic regression models; examination of variance inflation factors confirmed the absence of high correlation between covariates (n=16,085).\
**Abbreviations:** CDHP, consumer-driven health plan; HDHP, high deductible health plan; HMO, health maintenance organization; M, months; MAT, medication-assisted treatment; OUD, opioid use disorder; PDC, proportion of days covered; POS, point of service plan; PPO, preferred provider organization.](sar-9-059Fig2){#f2-sar-9-059}

![Predictors of adherence (PDC≥0.80) among adult patients with OUD who were newly initiating buprenorphine MAT: Medicaid sample.\
**Note:** Based on logistic regression models; examination of variance inflation factors confirmed the absence of high correlation between covariates (N=5,688).\
**Abbreviations:** M, months; MAT, medication-assisted treatment; OUD, opioid use disorder; PDC, proportion of days covered.](sar-9-059Fig3){#f3-sar-9-059}

###### 

Baseline demographic and clinical characteristics among adult patients with OUD who were newly initiating buprenorphine MAT: Commercial sample

                                                                                        All (n=16,085)   PDC\<0.20 (n=4,566)   *p*-value[a](#tfn1-sar-9-059){ref-type="table-fn"}   0.20≤PDC\<0.40 (n=2,119)   *p*-value[a](#tfn1-sar-9-059){ref-type="table-fn"}   0.40≤PDC\<0.60 (n=1,719)   *p*-value[a](#tfn1-sar-9-059){ref-type="table-fn"}   0.60≤PDC\<0.80 (n=1,718)   *p*-value[a](#tfn1-sar-9-059){ref-type="table-fn"}   PDC≥0.80 (n=5,963)
  ------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------------------------- -------------------------- ---------------------------------------------------- -------------------------- ---------------------------------------------------- -------------------------- ---------------------------------------------------- --------------------
  Age, mean (SD)                                                                        32.9 (12.7)      32.3 (13.4)           \<0.001                                              31.0 (12.5)                \<0.001                                              31.7 (12.7)                \<0.001                                              32.3 (12.4)                \<0.001                                              34.5 (12.1)
  Age group, n (%)                                                                                                             \<0.001                                                                         \<0.001                                                                         \<0.001                                                                         \<0.001                                              
   \<18 years                                                                           256 (1.6%)       79 (1.7%)                                                                  45 (2.1%)                                                                       33 (1.9%)                                                                       34 (2.0%)                                                                       65 (1.1%)
   18--24 years                                                                         6,221 (38.7%)    2,084 (45.6%)                                                              989 (46.7%)                                                                     766 (44.6%)                                                                     684 (39.8%)                                                                     1,698 (28.5%)
   25--34 years                                                                         3,201 (19.9%)    666 (14.6%)                                                                360 (17.0%)                                                                     302 (17.6%)                                                                     354 (20.6%)                                                                     1,519 (25.5%)
   35--44 years                                                                         2,735 (17.0%)    659 (14.4%)                                                                310 (14.6%)                                                                     252 (14.7%)                                                                     283 (16.5%)                                                                     1,231 (20.6%)
   45--54 years                                                                         2,482 (15.4%)    677 (14.8%)                                                                297 (14.0%)                                                                     252 (14.7%)                                                                     249 (14.5%)                                                                     1,007 (16.9%)
   55--64 years                                                                         1,190 (7.4%)     401 (8.8%)                                                                 118 (5.6%)                                                                      114 (6.6%)                                                                      114 (6.6%)                                                                      443 (7.4%)
  Sex, n (%)                                                                                                                   0.004                                                                           0.227                                                                           0.514                                                                           0.687                                                
   Male                                                                                 10,093 (62.7%)   2,792 (61.1%)                                                              1,322 (62.4%)                                                                   1,083 (63.0%)                                                                   1,088 (63.3%)                                                                   3,808 (63.9%)
   Female                                                                               5,992 (37.3%)    1,774 (38.9%)                                                              797 (37.6%)                                                                     636 (37.0%)                                                                     630 (36.7%)                                                                     2,155 (36.1%)
  Geographic region, n (%)                                                                                                     \<0.001                                                                         \<0.001                                                                         \<0.001                                                                         0.001                                                
   Northeast                                                                            4,125 (25.6%)    1,063 (23.3%)                                                              557 (26.3%)                                                                     389 (22.6%)                                                                     419 (24.4%)                                                                     1,697 (28.5%)
   Northcentral                                                                         4,017 (25.0%)    1,174 (25.7%)                                                              575 (27.1%)                                                                     415 (24.1%)                                                                     432 (25.1%)                                                                     1,421 (23.8%)
   South                                                                                4,549 (28.3%)    1,207 (26.4%)                                                              516 (24.4%)                                                                     534 (31.1%)                                                                     539 (31.4%)                                                                     1,753 (29.4%)
   West                                                                                 3,238 (20.1%)    1,090 (23.9%)                                                              454 (21.4%)                                                                     366 (21.3%)                                                                     317 (18.5%)                                                                     1,011 (17.0%)
   Unknown                                                                              156 (1.0%)       32 (0.7%)                                                                  17 (0.8%)                                                                       15 (0.9%)                                                                       11 (0.6%)                                                                       81 (1.4%)
  Urban/rural residence, n (%)                                                                                                 \<0.001                                                                         \<0.001                                                                         0.023                                                                           0.002                                                
   Urban                                                                                13,828 (86.0%)   4,025 (88.2%)                                                              1,866 (88.1%)                                                                   1,478 (86.0%)                                                                   1,486 (86.5%)                                                                   4,973 (83.4%)
   Rural                                                                                2,102 (13.1%)    509 (11.1%)                                                                237 (11.2%)                                                                     226 (13.1%)                                                                     221 (12.9%)                                                                     909 (15.2%)
   Unknown                                                                              155 (1.0%)       32 (0.7%)                                                                  16 (0.8%)                                                                       15 (0.9%)                                                                       11 (0.6%)                                                                       81 (1.4%)
  Insurance plan type, n (%)                                                                                                   \<0.001                                                                         0.001                                                                           0.002                                                                           0.444                                                
   Comprehensive/indemnity                                                              476 (3.0%)       145 (3.2%)                                                                 63 (3.0%)                                                                       48 (2.8%)                                                                       45 (2.6%)                                                                       175 (2.9%)
   EPO/PPO                                                                              9,394 (58.4%)    2,580 (56.5%)                                                              1,233 (58.2%)                                                                   1,018 (59.2%)                                                                   1,036 (60.3%)                                                                   3,527 (59.1%)
   POS/POS with capitation                                                              1,718 (10.7%)    475 (10.4%)                                                                218 (10.3%)                                                                     166 (9.7%)                                                                      198 (11.5%)                                                                     661 (11.1%)
   HMO                                                                                  2,407 (15.0%)    783 (17.1%)                                                                331 (15.6%)                                                                     274 (15.9%)                                                                     227 (13.2%)                                                                     792 (13.3%)
   CDHP/HDHP                                                                            954 (5.9%)       310 (6.8%)                                                                 139 (6.6%)                                                                      105 (6.1%)                                                                      93 (5.4%)                                                                       307 (5.1%)
   Others/unknown                                                                       1,136 (7.1%)     273 (6.0%)                                                                 135 (6.4%)                                                                      108 (6.3%)                                                                      119 (6.9%)                                                                      501 (8.4%)
  Relationship to policyholder, n (%)                                                                                          \<0.001                                                                         \<0.001                                                                         \<0.001                                                                         \<0.001                                              
   Employee (policyholder)                                                              5,884 (36.6%)    1,357 (29.7%)                                                              641 (30.3%)                                                                     534 (31.1%)                                                                     605 (35.2%)                                                                     2,747 (46.1%)
   Spouse                                                                               4,034 (25.1%)    1,101 (24.1%)                                                              488 (23.0%)                                                                     418 (24.3%)                                                                     426 (24.8%)                                                                     1,601 (26.8%)
   Child/others                                                                         6,167 (38.3%)    2,108 (46.2%)                                                              990 (46.7%)                                                                     767 (44.6%)                                                                     687 (40.0%)                                                                     1,615 (27.1%)
  Pre-index Charlson Comorbidity Index, mean (SD)                                       0.2 (0.7)        0.3 (0.7)             \<0.001                                              0.2 (0.7)                  0.082                                                0.2 (0.8)                  0.115                                                0.2 (0.6)                  0.590                                                0.2 (0.7)
  Pre-index comorbid conditions, n (%)                                                                                                                                                                                                                                                                                                                                                                                              
   Non-opioid drug use disorder                                                         4,566 (28.4%)    1,566 (34.3%)         \<0.001                                              664 (31.3%)                \<0.001                                              503 (29.3%)                \<0.001                                              457 (26.6%)                0.003                                                1,376 (23.1%)
   Alcohol use disorder                                                                 1,753 (10.9%)    606 (13.3%)           \<0.001                                              248 (11.7%)                \<0.001                                              190 (11.1%)                0.009                                                174 (10.1%)                0.145                                                535 (9.0%)
   Depressive disorder                                                                  4,711 (29.3%)    1,446 (31.7%)         \<0.001                                              621 (29.3%)                0.085                                                529 (30.8%)                0.005                                                484 (28.2%)                0.502                                                1,631 (27.4%)
   Bipolar disorder                                                                     1,124 (7.0%)     372 (8.1%)            \<0.001                                              160 (7.6%)                 \<0.001                                              141 (8.2%)                 \<0.001                                              128 (7.5%)                 0.002                                                323 (5.4%)
   Generalized anxiety disorder                                                         927 (5.8%)       271 (5.9%)            0.421                                                120 (5.7%)                 0.870                                                117 (6.8%)                 0.054                                                87 (5.1%)                  0.418                                                332 (5.6%)
   Schizophrenia                                                                        68 (0.4%)        29 (0.6%)             N/A                                                  13 (0.6%)                  N/A                                                  \<10 (\<0.6%)              N/A                                                  \<10 (\<0.6%)              N/A                                                  16 (0.3%)
   Chronic pain condition                                                               7,306 (45.4%)    2,129 (46.6%)         0.725                                                902 (42.6%)                \<0.001                                              716 (41.7%)                \<0.001                                              758 (44.1%)                0.037                                                2,801 (47.0%)
   HIV/AIDS                                                                             24 (0.1%)        10 (0.2%)             N/A                                                  \<10 (\<0.5%)              N/A                                                  \<10 (\<0.6%)              N/A                                                  \<10 (\<0.6%)              N/A                                                  \<10 (\<0.2%)
  Hepatitis B                                                                           22 (0.1%)        \<10 (\<0.2%)         N/A                                                  \<10 (\<0.5%)              N/A                                                  \<10 (\<0.6%)              N/A                                                  \<10 (\<0.6%)              N/A                                                  \<10 (\<0.2%)
   Hepatitis C                                                                          360 (2.2%)       128 (2.8%)            \<0.001                                              50 (2.4%)                  0.052                                                44 (2.6%)                  0.020                                                37 (2.2%)                  0.206                                                101 (1.7%)
  Pre-index concomitant medications, n (%)                                                                                                                                                                                                                                                                                                                                                                                          
   Opioid analgesicsb                                                                   8,497 (52.8%)    2,411 (52.8%)         0.004                                                1,039 (49.0%)              \<0.001                                              835 (48.6%)                \<0.001                                              896 (52.2%)                0.011                                                3,316 (55.6%)
   Benzodiazepines                                                                      4,695 (29.2%)    1,390 (30.4%)         0.015                                                630 (29.7%)                0.203                                                509 (29.6%)                0.280                                                480 (27.9%)                0.786                                                1,686 (28.3%)
   Non-benzodiazepine; sedative/hypnotics                                               3,467 (21.6%)    1,031 (22.6%)         0.016                                                476 (22.5%)                0.075                                                376 (21.9%)                0.263                                                354 (20.6%)                0.984                                                1,230 (20.6%)
   Antidepressants                                                                      7,336 (45.6%)    2,092 (45.8%)         0.695                                                924 (43.6%)                0.039                                                793 (46.1%)                0.959                                                772 (44.9%)                0.354                                                2,755 (46.2%)
   Antipsychotics                                                                       1,969 (12.2%)    614 (13.4%)           \<0.001                                              289 (13.6%)                \<0.001                                              226 (13.1%)                0.002                                                216 (12.6%)                0.014                                                624 (10.5%)
  Average daily dose of buprenorphine,[c](#tfn3-sar-9-059){ref-type="table-fn"} n (%)                                          \<0.001                                                                         \<0.001                                                                         \<0.001                                                                         \<0.001                                              
   ≤4 mg                                                                                825 (5.1%)       395 (8.7%)                                                                 120 (5.7%)                                                                      82 (4.8%)                                                                       65 (3.8%)                                                                       163 (2.7%)
   \>4--8 mg                                                                            3,099 (19.3%)    1,364 (29.9%)                                                              425 (20.1%)                                                                     284 (16.5%)                                                                     249 (14.5%)                                                                     777 (13.0%)
   \>8--12 mg                                                                           2,621 (16.3%)    644 (14.1%)                                                                384 (18.1%)                                                                     307 (17.9%)                                                                     342 (19.9%)                                                                     944 (15.8%)
   \>12--16 mg                                                                          5,018 (31.2%)    1,285 (28.1%)                                                              659 (31.1%)                                                                     555 (32.3%)                                                                     551 (32.1%)                                                                     1,968 (33.0%)
   \>16--20 mg                                                                          1,862 (11.6%)    328 (7.2%)                                                                 245 (11.6%)                                                                     214 (12.4%)                                                                     208 (12.1%)                                                                     867 (14.5%)
   \>20--24 mg                                                                          1,970 (12.2%)    399 (8.7%)                                                                 222 (10.5%)                                                                     204 (11.9%)                                                                     223 (13.0%)                                                                     922 (15.5%)
   \>24 mg                                                                              690 (4.3%)       151 (3.3%)                                                                 64 (3.0%)                                                                       73 (4.2%)                                                                       80 (4.7%)                                                                       322 (5.4%)

**Notes:**

Based on comparison with the PDC≥0.80 group.

Excluding buprenorphine and methadone.

Measured during the first 6 months of the post-index period.

**Abbreviations:** CDHP, consumer-driven health plan; EPO, exclusive provider organization; HDHP, high deductible health plan; HMO, health maintenance organization; MAT, medication-assisted treatment; OUD, opioid use disorder; PDC, proportion of days covered; POS, point of service plan; PPO, preferred provider organization; N/A, not applicable.

###### 

Baseline demographic and clinical characteristics among adult patients with OUD who were newly initiating buprenorphine MAT: Medicaid sample

                                                                                        All (n=5,688)   PDC\<0.20 (n=1,519)   *p*-value[a](#tfn5-sar-9-059){ref-type="table-fn"}   0.20≤PDC\<0.40 (n=716)   *p*-value[a](#tfn5-sar-9-059){ref-type="table-fn"}   0.40≤PDC\<0.60 (n=595)   *p*-value[a](#tfn5-sar-9-059){ref-type="table-fn"}   0.60≤PDC\<0.80 (n=507)   *p*-value[a](#tfn5-sar-9-059){ref-type="table-fn"}   PDC≥0.80 (n=2,351)
  ------------------------------------------------------------------------------------- --------------- --------------------- ---------------------------------------------------- ------------------------ ---------------------------------------------------- ------------------------ ---------------------------------------------------- ------------------------ ---------------------------------------------------- --------------------
  Age, mean (SD)                                                                        32.4 (9.4)      33.2 (10.4)           0.022                                                31.1 (9.2)               \<0.001                                              31.7 (8.9)               0.051                                                32.0 (9.2)               0.316                                                32.5 (8.9)
  Age group, n (%)[b](#tfn6-sar-9-059){ref-type="table-fn"}                                                                   \<0.001                                                                       \<0.001                                                                       0.027                                                                         0.434                                                
   ≤24 years                                                                            1,111 (19.5%)   319 (21.0%)                                                                182 (25.4%)                                                                   125 (21.0%)                                                                   99 (19.5%)                                                                    386 (16.4%)
   25--34 years                                                                         2,683 (47.2%)   622 (40.9%)                                                                333 (46.5%)                                                                   282 (47.4%)                                                                   251 (49.5%)                                                                   1,195 (50.8%)
   35--44 years                                                                         1,179 (20.7%)   329 (21.7%)                                                                127 (17.7%)                                                                   133 (22.4%)                                                                   96 (18.9%)                                                                    494 (21.0%)
   45--54 years                                                                         543 (9.5%)      184 (12.1%)                                                                59 (8.2%)                                                                     45 (7.6%)                                                                     48 (9.5%)                                                                     207 (8.8%)
   55--65+ years                                                                        172 (3.0%)      65 (4.3%)                                                                  15 (2.1%)                                                                     10 (1.7%)                                                                     13 (2.6%)                                                                     69 (2.9%)
  Sex, n (%)                                                                                                                  0.002                                                                         0.693                                                                         0.686                                                                         0.840                                                
   Male                                                                                 1,561 (27.4%)   466 (30.7%)                                                                192 (26.8%)                                                                   160 (26.9%)                                                                   130 (25.6%)                                                                   613 (26.1%)
   Female                                                                               4,127 (72.6%)   1,053 (69.3%)                                                              524 (73.2%)                                                                   435 (73.1%)                                                                   377 (74.4%)                                                                   1,738 (73.9%)
  Race, n (%)                                                                                                                 \<0.001                                                                       0.810                                                                         0.660                                                                         0.552                                                
   White                                                                                4,943 (86.9%)   1,262 (83.1%)                                                              634 (88.5%)                                                                   521 (87.6%)                                                                   452 (89.2%)                                                                   2,074 (88.2%)
   Non-White/unknown                                                                    745 (13.1%)     257 (16.9%)                                                                82 (11.5%)                                                                    74 (12.4%)                                                                    55 (10.8%)                                                                    277 (11.8%)
  Urban/rural residence, n (%)                                                                                                0.001                                                                         0.448                                                                         0.129                                                                         0.034                                                
   Urban                                                                                3,688 (64.8%)   1,062 (69.9%)                                                              443 (61.9%)                                                                   373 (62.7%)                                                                   297 (58.6%)                                                                   1,513 (64.4%)
   Rural                                                                                1,860 (32.7%)   421 (27.7%)                                                                254 (35.5%)                                                                   200 (33.6%)                                                                   200 (39.4%)                                                                   785 (33.4%)
   Unknown                                                                              140 (2.5%)      36 (2.4%)                                                                  19 (2.7%)                                                                     22 (3.7%)                                                                     10 (2.0%)                                                                     53 (2.3%)
  Insurance plan type, n (%)[c](#tfn7-sar-9-059){ref-type="table-fn"}                                                         \<0.001                                                                       \<0.001                                                                       \<0.001                                                                       \<0.001                                              
   Non-managed care                                                                     4,028 (70.8%)   1,007 (66.3%)                                                              485 (67.7%)                                                                   391 (65.7%)                                                                   338 (66.7%)                                                                   1,807 (76.9%)
   Medicaid managed care                                                                1,660 (29.2%)   512 (33.7%)                                                                231 (32.3%)                                                                   204 (34.3%)                                                                   169 (33.3%)                                                                   544 (23.1%)
  Pre-index Charlson Comorbidity Index, mean (SD)                                       0.4 (0.9)       0.5 (1.2)             \<0.001                                              0.4 (1.0)                0.068                                                0.3 (0.7)                0.187                                                0.3 (0.8)                0.202                                                0.3 (0.8)
  Pre-index comorbid conditions, n (%)                                                                                                                                                                                                                                                                                                                                                                                       
   Non-opioid drug use disorder                                                         2,176 (38.3%)   685 (45.1%)           \<0.001                                              282 (39.4%)              0.002                                                232 (39.0%)              0.008                                                197 (38.9%)              0.014                                                780 (33.2%)
   Alcohol use disorder                                                                 559 (9.8%)      196 (12.9%)           \<0.001                                              65 (9.1%)                0.301                                                61 (10.3%)               0.060                                                52 (10.3%)               0.077                                                185 (7.9%)
   Depressive disorder                                                                  2,306 (40.5%)   650 (42.8%)           0.005                                                304 (42.5%)              0.045                                                246 (41.3%)              0.171                                                206 (40.6%)              0.325                                                900 (38.3%)
   Bipolar disorder                                                                     1,024 (18.0%)   335 (22.1%)           \<0.001                                              126 (17.6%)              0.159                                                116 (19.5%)              0.015                                                85 (16.8%)               0.442                                                362 (15.4%)
   Generalized anxiety disorder                                                         606 (10.7%)     161 (10.6%)           0.745                                                85 (11.9%)               0.484                                                61 (10.3%)               0.633                                                42 (8.3%)                0.077                                                257 (10.9%)
   Schizophrenia                                                                        148 (2.6%)      59 (3.9%)             \<0.001                                              20 (2.8%)                0.043                                                14 (2.4%)                0.223                                                17 (3.4%)                0.010                                                38 (1.6%)
   Chronic pain condition                                                               3,290 (57.8%)   924 (60.8%)           \<0.001                                              437 (61.0%)              0.004                                                351 (59.0%)              0.074                                                287 (56.6%)              0.486                                                1,291 (54.9%)
   HIV/AIDS                                                                             48 (0.8%)       22 (1.4%)             0.002                                                11 (1.5%)                0.005                                                \<10 (\<1.7%)            N/A                                                  \<10 (\<2.0%)            N/A                                                  12 (0.5%)
   Hepatitis B                                                                          27 (0.5%)       \<10 (\<0.7%)         N/A                                                  \<10 (\<1.4%)            N/A                                                  \<10 (\<1.7%)            N/A                                                  \<10 (\<2.0%)            N/A                                                  13 (0.6%)
   Hepatitis C                                                                          465 (8.2%)      151 (9.9%)            0.001                                                55 (7.7%)                0.470                                                57 (9.6%)                0.025                                                40 (7.9%)                0.426                                                162 (6.9%)
  Pre-index concomitant medications, n (%)                                                                                                                                                                                                                                                                                                                                                                                   
   Opioid analgesics[d](#tfn8-sar-9-059){ref-type="table-fn"}                           3,681 (64.7%)   1,009 (66.4%)         0.007                                                493 (68.9%)              0.001                                                389 (65.4%)              0.150                                                328 (64.7%)              0.290                                                1,462 (62.2%)
   Benzodiazepines                                                                      1,883 (33.1%)   564 (37.1%)           \<0.001                                              252 (35.2%)              0.007                                                198 (33.3%)              0.106                                                167 (32.9%)              0.172                                                702 (29.9%)
   Non-benzodiazepine; sedative/hypnotic                                                1,298 (22.8%)   387 (25.5%)           \<0.001                                              191 (26.7%)              \<0.001                                              143 (24.0%)              0.028                                                108 (21.3%)              0.491                                                469 (19.9%)
   Antidepressants                                                                      2,794 (49.1%)   812 (53.5%)           \<0.001                                              352 (49.2%)              0.203                                                293 (49.2%)              0.222                                                245 (48.3%)              0.443                                                1,092 (46.4%)
   Antipsychotics                                                                       1,075 (18.9%)   349 (23.0%)           \<0.001                                              133 (18.6%)              0.206                                                116 (19.5%)              0.088                                                88 (17.4%)               0.657                                                389 (16.5%)
  Average daily dose of buprenorphine,[e](#tfn9-sar-9-059){ref-type="table-fn"} n (%)                                         \<0.001                                                                       \<0.001                                                                       \<0.001                                                                       0.140                                                
   ≤8 mg                                                                                819 (14.4%)     450 (29.6%)                                                                104 (14.5%)                                                                   77 (12.9%)                                                                    44 (8.7%)                                                                     144 (6.1%)
   \>8--12 mg                                                                           605 (10.6%)     156 (10.3%)                                                                95 (13.3%)                                                                    82 (13.8%)                                                                    56 (11.0%)                                                                    216 (9.2%)
   \>12--16 mg                                                                          1,876 (33.0%)   502 (33.0%)                                                                245 (34.2%)                                                                   170 (28.6%)                                                                   170 (33.5%)                                                                   789 (33.6%)
   \>16--20 mg                                                                          806 (14.2%)     140 (9.2%)                                                                 96 (13.4%)                                                                    91 (15.3%)                                                                    82 (16.2%)                                                                    397 (16.9%)
   \>20--24 mg                                                                          1,230 (21.6%)   223 (14.7%)                                                                139 (19.4%)                                                                   135 (22.7%)                                                                   123 (24.3%)                                                                   610 (25.9%)
   \>24 mg                                                                              352 (6.2%)      48 (3.2%)                                                                  37 (5.2%)                                                                     40 (6.7%)                                                                     32 (6.3%)                                                                     195 (8.3%)

**Notes:**

Based on comparison with the PDC≥0.80 group.

Few patients were aged \<18 years (n=55) or aged 65+ years (n\<10), so age group categories were combined.

Medicaid managed care included patients in POS plans with capitation or HMO plans. All other plan types were considered non-managed care. Few patients had an unknown plan type (n\<10); these patients were combined with the non-managed care group.

Excluding buprenorphine and methadone.

Measured during the first 6 months of the post-index period. Of 148 patients with a dose of ≤4 mg, 105 were in the PDC\<0.20 group, but few (n\<10) were in some other PDC categories; thus, the ≤4 mg and \>4--8 mg average daily dose categories were combined.

**Abbreviations:** HMO, health maintenance organization; MAT, medication-assisted treatment; OUD, opioid use disorder; PDC, proportion of days covered; POS, point of service; N/A, not applicable.

###### 

Unadjusted relapse prevalence, health care resource utilization and costs in the 12-month post-index period among adult patients with OUD who were newly initiating buprenorphine MAT

                                                                                                            Commercial sample (n =16,085)                                                                                                                                   
  --------------------------------------------------------------------------------------------------------- ------------------------------- --------------------- --------- --------------------- --------- --------------------- --------- --------------------- --------- ---------------------
  Relapse prevalence in the 12-month post-index period, n (%)                                                                                                                                                                                                               
   Continuous/episodic dependence following remission diagnosis                                             355 (2.2%)                      45 (1.0%)             \<0.001   52 (2.5%)             0.544     48 (2.8%)             0.836     49 (2.9%)             0.733     161 (2.7%)
   Inpatient admission, primary diagnosis related to opioid use[b](#tfn12-sar-9-059){ref-type="table-fn"}   1,838 (11.4%)                   784 (17.2%)           \<0.001   380 (17.9%)           \<0.001   267 (15.5%)           \<0.001   179 (10.4%)           \<0.001   228 (3.8%)
   Detoxification, any diagnosis related to opioid use                                                      1,893 (11.8%)                   739 (16.2%)           \<0.001   398 (18.8%)           \<0.001   276 (16.1%)           \<0.001   195 (11.4%)           \<0.001   285 (4.8%)
   ED visit, any diagnosis related to opioid use                                                            1,195 (7.4%)                    485 (10.6%)           \<0.001   227 (10.7%)           \<0.001   144 (8.4%)            \<0.001   123 (7.2%)            \<0.001   216 (3.6%)
   Any of the abovementioned relapse indicators                                                             3,404 (21.2%)                   1,288 (28.2%)         \<0.001   640 (30.2%)           \<0.001   444 (25.8%)           \<0.001   351 (20.4%)           \<0.001   681 (11.4%)
  Utilization in the 12-month post-index period                                                                                                                                                                                                                             
   Patients with an inpatient admission, n (%)                                                              5,122 (31.8%)                   2,025 (44.3%)         \<0.001   869 (41.0%)           \<0.001   644 (37.5%)           \<0.001   517 (30.1%)           \<0.001   1,067 (17.9%)
   Patients with any ED visit, n (%)                                                                        7,314 (45.5%)                   2,512 (55.0%)         \<0.001   1,175 (55.5%)         \<0.001   828 (48.2%)           \<0.001   742 (43.2%)           \<0.001   2,057 (34.5%)
   Number of physician office visits per patient, mean (SD)                                                 11.2 (10.0)                     8.9 (10.1)            \<0.001   9.9 (9.4)             0.046     10.7 (9.1)            0.015     12.1 (10.2)           0.717     13.2 (10.0)
   Number of outpatient pharmacy claims per patient, mean (SD)                                              37.9 (29.7)                     33.2 (33.5)           \<0.001   34.6 (31.0)           \<0.001   37.2 (28.5)           \<0.001   39.6 (26.5)           \<0.001   42.3 (26.4)
  Costs in the 12-month post-index period, mean (SD)                                                                                                                                                                                                                        
   Inpatient costs                                                                                          \$6,555 (\$33,613)              \$10,953 (\$55,006)   \<0.001   \$8,792 (\$27,193)    \<0.001   \$7,633 (\$25,619)    \<0.001   \$5,689 (\$22,657)    \<0.001   \$2,330 (\$9,832)
   Outpatient costs                                                                                         \$11,211 (\$19,477)             \$14,212 (\$24,842)   \<0.001   \$12,436 (\$20,936)   \<0.001   \$12,689 (\$22,102)   \<0.001   \$10,556 (\$21,553)   \<0.001   \$8,239 (\$10,181)
    ED costs                                                                                                \$1,029 (\$2,905)               \$1,510 (\$3,742)     \<0.001   \$1,386 (\$3,999)     \<0.001   \$1,162 (\$2,932)     \<0.001   \$842 (\$1,999)       \<0.001   \$549 (\$1,504)
    Outpatient physician office visit costs                                                                 \$1,199 (\$1,235)               \$988 (\$1,280)       \<0.001   \$1,100 (\$1,185)     \<0.001   \$1,175 (\$1,272)     \<0.001   \$1,299 (\$1,242)     0.023     \$1,373 (\$1,173)
    Other outpatient costs                                                                                  \$8,983 (\$18,330)              \$11,715 (\$23,460)   \<0.001   \$9,950 (\$18,987)    \<0.001   \$10,352 (\$21,103)   \<0.001   \$8,415 (\$20,929)    \<0.001   \$6,317 (\$9,416)
   Medical costs                                                                                            \$17,765 (\$42,537)             \$25,165 (\$64,377)   \<0.001   \$21,228 (\$39,620)   \<0.001   \$20,322 (\$39,815)   \<0.001   \$16,245 (\$34,271)   \<0.001   \$10,570 (\$15,694)
   Outpatient pharmacy costs                                                                                \$5,241 (\$6,073)               \$3,360 (\$6,707)     \<0.001   \$3,800 (\$5,694)     \<0.001   \$4,635 (\$5,506)     \<0.001   \$5,561 (\$5,322)     \<0.001   \$7,275 (\$5,379)
  Total health care costs, mean (SD)                                                                        \$23,006 (\$43,643)             \$28,525 (\$65,851)   \<0.001   \$25,028 (\$41,114)   \<0.001   \$24,957 (\$41,455)   \<0.001   \$21,806 (\$35,278)   \<0.001   \$17,844 (\$17,642)
  Relapse prevalence in the 12-month post-index period, n (%)                                                                                                                                                                                                               
   Continuous/episodic dependence following remission diagnosis                                             141 (2.5%)                      11 (0.7%)             \<0.001   9 (1.3%)              0.002     21 (3.5%)             0.961     18 (3.6%)             0.945     82 (3.5%)
   Inpatient admission, primary diagnosis related to opioid use[b](#tfn12-sar-9-059){ref-type="table-fn"}   96 (1.7%)                       44 (2.9%)             \<0.001   17 (2.4%)             \<0.001   14 (2.4%)             \<0.001   \<10 (\<2.0%)         N/A       14 (0.6%)
   Detoxification, any diagnosis related to opioid use                                                      129 (2.3%)                      58 (3.8%)             \<0.001   25 (3.5%)             \<0.001   17 (2.9%)             \<0.001   11 (2.2%)             0.004     18 (0.8%)
   ED visit, any diagnosis related to opioid use                                                            604 (10.6%)                     228 (15.0%)           \<0.001   118 (16.5%)           \<0.001   62 (10.4%)            \<0.001   56 (11.0%)            \<0.001   140 (6.0%)
   Any of the abovementioned relapse indicators                                                             853 (15.0%)                     296 (19.5%)           \<0.001   142 (19.8%)           \<0.001   100 (16.8%)           \<0.001   80 (15.8%)            \<0.001   235 (10.0%)
  Utilization in the 12-month post-index period                                                                                                                                                                                                                             
   Patients with an inpatient admission, n (%)                                                              1,645 (28.9%)                   592 (39.0%)           \<0.001   255 (35.6%)           \<0.001   185 (31.1%)           \<0.001   145 (28.6%)           \<0.001   468 (19.9%)
   Patients with any ED visit, n (%)                                                                        4,133 (72.7%)                   1,209 (79.6%)         \<0.001   569 (79.5%)           \<0.001   450 (75.6%)           \<0.001   376 (74.2%)           \<0.001   1,529 (65.0%)
   Number of physician office visits per patient, mean (SD)                                                 10.6 (9.4)                      8.3 (8.0)             \<0.001   9.2 (7.5)             \<0.001   10.1 (8.6)            \<0.001   11.3 (8.8)            0.006     12.6 (10.5)
   Number of outpatient pharmacy claims per patient, mean (SD)                                              47.6 (34.3)                     42.6 (39.9)           \<0.001   41.1 (32.6)           \<0.001   46.6 (32.5)           \<0.001   50.1 (32.0)           0.128     52.4 (31.0)
  Costs in the 12-month post-index period, mean (SD)                                                                                                                                                                                                                        
   Inpatient costs                                                                                          \$5,600 (\$30,440)              \$8,914 (\$42,990)    \<0.001   \$8,535 (\$44,359)    \<0.001   \$6,888 (\$26,534)    \<0.001   \$5,137 (\$24,979)    \<0.001   \$2,339 (\$10,804)
   Outpatient costs                                                                                         \$8,407 (\$9,120)               \$8,822 (\$9,730)     0.009     \$8,583 (\$11,701)    0.181     \$8,511 (\$8,355)     0.234     \$8,386 (\$8,179)     0.420     \$8,064 (\$8,135)
    ED costs                                                                                                \$1,115 (\$2,327)               \$1,604 (\$2,883)     \<0.001   \$1,543 (\$3,654)     \<0.001   \$1,217 (\$2,127)     \<0.001   \$1,027 (\$1,617)     \<0.001   \$661 (\$1,243)
    Outpatient physician office visit costs                                                                 \$863 (\$862)                   \$654 (\$665)         \<0.001   \$744 (\$667)         \<0.001   \$827 (\$789)         \<0.001   \$916 (\$840)         0.014     \$1,033 (\$1,003)
    Other outpatient costs                                                                                  \$6,429 (\$8,035)               \$6,565 (\$8,082)     0.447     \$6,296 (\$10,218)    0.834     \$6,467 (\$7,164)     0.778     \$6,442 (\$7,459)     0.845     \$6,370 (\$7,569)
   Medical costs                                                                                            \$14,008 (\$33,413)             \$17,737 (\$46,395)   \<0.001   \$17,118 (\$47,841)   \<0.001   \$15,398 (\$30,027)   \<0.001   \$13,523 (\$27,473)   \<0.001   \$10,403 (\$14,114)
   Outpatient pharmacy costs                                                                                \$5,880 (\$7,316)               \$3,555 (\$7,621)     \<0.001   \$4,136 (\$7,502)     \<0.001   \$4,665 (\$4,223)     \<0.001   \$5,896 (\$4,396)     \<0.001   \$8,218 (\$7,480)
  Total health care costs, mean (SD)                                                                        \$19,888 (\$34,652)             \$21,292 (\$47,595)   0.013     \$21,254 (\$48,923)   0.027     \$20,063 (\$31,044)   0.128     \$19,419 (\$28,713)   0.406     \$18,621 (\$17,020)

**Notes:**

Based on comparison with the PDC≥0.80 group.

Diagnoses related to opioid use included opioid dependence, opioid abuse or opioid overdose.

**Abbreviations:** ED, emergency department; MAT, medication-assisted treatment; OUD, opioid use disorder; PDC, proportion of days covered; N/A, not applicable.

###### 

Adjusted odds of at least one indicator of relapse in the 12-month post-index period among adult patients with OUD who were newly initiating buprenorphine MAT[a](#tfn14-sar-9-059){ref-type="table-fn"}

  Effect[b](#tfn15-sar-9-059){ref-type="table-fn"}            Commercial sample (n=16,085)   Medicaid sample (n=5,688)                        
  ----------------------------------------------------------- ------------------------------ --------------------------- ------ ------ ------ ------
  PDC: \<0.20 (vs. PDC≥0.80)                                  2.02                           1.77                        2.32   1.76   1.40   2.20
  PDC: 0.20≤PDC\<0.40 (vs. PDC≥0.80)                          2.33                           1.99                        2.74   1.90   1.45   2.50
  PDC: 0.40≤PDC\<0.60 (vs. PDC≥0.80)                          2.27                           1.92                        2.70   1.65   1.22   2.23
  PDC: 0.60≤PDC\<0.80 (vs. PDC≥0.80)                          1.65                           1.37                        1.98   1.48   1.06   2.06
  Age                                                         0.99                           0.98                        0.99   0.98   0.97   0.99
  Female sex (vs. male)                                       0.97                           0.87                        1.08   0.87   0.72   1.07
  Black race (vs. White)                                      N/A                            N/A                         N/A    1.24   0.89   1.75
  Hispanic race (vs. White)                                   N/A                            N/A                         N/A    1.16   0.49   2.75
  Other race (vs. White)                                      N/A                            N/A                         N/A    1.52   1.06   2.18
  Spouse relationship to policyholder (vs. employee)          1.01                           0.86                        1.19   N/A    N/A    N/A
  Child/other relationship to policyholder (vs. employee)     2.02                           1.69                        2.42   N/A    N/A    N/A
  Comprehensive/indemnity insurance plan type (vs. EPO/PPO)   1.51                           1.15                        2.00   N/A    N/A    N/A
  POS/POS with capitation insurance plan type (vs. EPO/PPO)   0.90                           0.76                        1.07   N/A    N/A    N/A
  HMO insurance plan type (vs. EPO/PPO)                       0.99                           0.86                        1.14   N/A    N/A    N/A
  CDHP/HDHP insurance plan type (vs. EPO/PPO)                 0.91                           0.74                        1.21   N/A    N/A    N/A
  Medicaid managed care plan type (vs. non-managed care)      N/A                            N/A                         N/A    1.10   0.91   1.34
  Pre-index alcohol use disorder diagnosis (vs. no)           1.22                           1.05                        1.42   1.18   0.90   1.56
  Pre-index non-opioid drug use disorder diagnosis (vs. no)   1.30                           1.17                        1.45   1.41   1.17   1.71
  Pre-index severe mental illness diagnosis (vs. no)          1.15                           0.96                        1.38   1.37   1.11   1.70
  Pre-index other mental illness diagnosis (vs. no)           1.17                           1.04                        1.31   1.02   0.85   1.23
  Pre-index chronic pain condition diagnosis (vs. no)         0.97                           0.87                        1.09   1.07   0.89   1.29

**Notes:**

Based on logistic regression models; examination of variance inflation factors confirmed the absence of high correlation between covariates.

Covariates differed for the Commercial and Medicaid models due to differences in the underlying databases used for the analysis; variables not included in a model are denoted with "N/A".

**Abbreviations:** CDHP, consumer-driven health plan; EPO, exclusive provider organization; HDHP, high deductible health plan; HMO, health maintenance organization; MAT, medication-assisted treatment; OUD, opioid use disorder; PDC, proportion of days covered; POS, point of service plan; PPO, preferred provider organization; N/A, not applicable.

###### 

Adjusted total costs in the 12-month post-index period based on GLMs among adult patients with OUD who were newly initiating buprenorphine MAT[a](#tfn17-sar-9-059){ref-type="table-fn"}

                                                           Explanatory variable[b](#tfn18-sar-9-059){ref-type="table-fn"}   Patient group   Mean        Standard error   Difference in mean   Standard error of the difference   95% lower simultaneous confidence limit[c](#tfn19-sar-9-059){ref-type="table-fn"}   95% upper simultaneous confidence limit[c](#tfn19-sar-9-059){ref-type="table-fn"}
  -------------------------------------------------------- ---------------------------------------------------------------- --------------- ----------- ---------------- -------------------- ---------------------------------- ----------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Commercial sample (n=16,085)                             PDC                                                              \<0.20          \$24,431    \$403            --\$6,912            \$482                              --\$8,208                                                                           --\$5,616
  0.20 to \<0.40                                           \$22,697                                                         \$506           --\$5,178   \$570            --\$6,712            --\$3,644                                                                                                              
  0.40 to \<0.60                                           \$22,878                                                         \$555           --\$5,359   \$614            --\$7,012            --\$3,706                                                                                                              
  0.60 to \<0.80                                           \$20,294                                                         \$493           --\$2,775   \$559            --\$4,278            --\$1,272                                                                                                              
  ≥0.80[d](#tfn20-sar-9-059){ref-type="table-fn"}          \$17,519                                                         \$264                                                                                                                                                                                    
  Relationship to policyholder                             Child/others                                                     \$27,073        \$505       \$8,503          \$594                \$7,338                            \$9,668                                                                             
  Spouse                                                   \$20,325                                                         \$400           \$1,755     \$508            \$759                \$2,751                                                                                                                
  Employee[d](#tfn20-sar-9-059){ref-type="table-fn"}       \$18,570                                                         \$313                                                                                                                                                                                    
  Pre-index chronic pain condition                         Yes                                                              \$24,995        \$378       \$6,155          \$465                \$5,243                            \$7,067                                                                             
  No[d](#tfn20-sar-9-059){ref-type="table-fn"}             \$18,840                                                         \$272                                                                                                                                                                                    
  Medicaid sample (n=5,688)                                PDC                                                              PDC\<0.20       \$18,202    \$693            \$1,810              \$1,015                            --\$921                                                                             \$4,541
  0.20≤PDC\<0.40                                           \$20,119                                                         \$902           --\$107     \$1,168          --\$3,248            \$3,034                                                                                                                
  0.40≤PDC\<0.60                                           \$19,387                                                         \$912           \$625       \$1,175          --\$2,536            \$3,786                                                                                                                
  0.60≤PDC\<0.80                                           \$18,710                                                         \$921           \$1,302     \$1,182          --\$1,878            \$4,482                                                                                                                
  PDC≥0.80[d](#tfn20-sar-9-059){ref-type="table-fn"}       \$20,012                                                         \$742                                                                                                                                                                                    
  Insurance plan type                                      Non-managed care                                                 \$19,371        \$703       --\$3,406        \$1,144              --\$5,649                          --\$1,163                                                                           
  Managed care[d](#tfn20-sar-9-059){ref-type="table-fn"}   \$22,777                                                         \$903                                                                                                                                                                                    
  Pre-index severe mental illness                          Yes                                                              \$24,146        \$1,018     \$5,873          \$1,202              \$3,518                            \$8,228                                                                             
  No[d](#tfn20-sar-9-059){ref-type="table-fn"}             \$18,273                                                         \$639                                                                                                                                                                                    

**Notes:**

Based on GLMs, with model coefficients for the explanatory variable used to adjust costs. Model covariates included PDC, age, sex, race (Medicaid only), relationship to policyholder (Commercial only), insurance plan type, pre-index diagnosis of alcohol use disorder, non-opioid drug use disorder, severe mental illness (schizophrenia and/or bipolar disorder diagnosis), other mental illnesses (depressive disorder and/or generalized anxiety disorder diagnosis) and chronic pain condition.

The explanatory variable of interest in this analysis was PDC. Adjusted costs are shown for the PDC groups and other variables that the analyses suggested may be cost drivers (Commercial: relationship to policyholder, pre-index chronic pain condition; Medicaid: insurance plan type, pre-index severe mental illness).

The 95% upper and lower confidence limits are around the difference in mean.

Reference category.

**Abbreviations:** GLMs, generalized linear models; MAT, medication-assisted treatment; OUD, opioid use disorder; PDC, proportion of days covered.
